Skip to main content

Core Industry Metrics

As part of our mission to be the industry’s go-to source for market data, we provide and update this repository of core pharmaceutical industry metrics free to interested parties. To download the raw data MS Excel sets, use the links below.

CRO Core Metrics   |   CMO Core Metrics   |   Other Core Industry Metrics

Excel sets last updated: September 2022 with data from Q2, 2022

*IQVIA (Quintiles) total gross revenue has been adjusted to the proportion related to R&D solutions. =0.647
PRA and ICON merged in July, 2021 – data will be combined going forward (Q3, 2021)

*Celltrion removed because financials include innovator drugs and CDMO services.

*Companies included: Viatris, Teva, Sun Pharmaceutical, Aurobindo, Lupin
**Innovator companies and companies with medical device offerings omitted from above rankings.

*Companies included: J&J, Pfizer, Roche, Novartis, Merck & Co., GlaxoSmithKline, Sanofi, AbbVie, Takeda, Shanghai Pharmaceuticals

Top 20 Drug Sales

Source: https://www.fiercepharma.com/special-report/top-20-drugs-by-2020-sales

No.
Drug Name
Active Ingredient
Approval Date
FDA-approved use on approval date*
1
Quviviq
daridorexant
1/7/22
To treat insomnia
2
Cibinqo
abrocitinib
1/14/22
To treat refractory, moderate-to-severe atopic dermatitis
3
Kimmtrak
tebentafusp-tebn
1/25/22
To treat unresectable or metastatic uveal melanoma
4
Vabysmo
faricimab-svoa
1/28/22
To treat neovascular (wet) aged-related macular degeneration and diabetic macular edema
5
Enjaymo
sutimlimab-jome
2/4/22
To decrease the need for red blood cell transfusion due to hemolysis in cold agglutinin disease
6
Pyrukynd
mitapivat
2/17/22
To treat hemolytic anemia in pyruvate kinase deficiency
7
Vonjo
pacritinib
2/28/22
To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets
8
Ztalmy
ganaxolone
3/18/22
To treat seizures in cyclin-dependent kinase-like 5 deficiency disorder
9
Opdualag
nivolumab and relatlimab-rmbw
3/18/22
To treat unresectable or metastatic melanoma
10
Pluvicto
lutetium (177Lu) vipivotide tetraxetan
3/23/22
To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies
11
Vivjoa
oteseconazole
4/26/22
To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential
12
Voquezna
vonoprazan, amoxicillin, and clarithromycin
5/3/22
To treat Helicobacter pylori infection
13
Camzyos
mavacamten
4/28/22
To treat certain classes of obstructive hypertrophic cardiomyopathy
14
Vtama
tapinarof
5/23/22
To treat plaque psoriasis
15
Mounjaro
tirzepatide
5/13/22
To improve blood sugar control in diabetes, in addition to diet and exercise  Press Release
16
Amvuttra
vutrisiran
6/13/22
To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
17
Xenpozyme
Olipudase alfa
8/31/22
To treat Acid Sphingomyelinase Deficiency
18
Spevigo
spesolimab-sbzo
9/1/22
To treat generalized pustular psoriasis flares
19
Daxxify
daxibotulinumtoixnA-lanm
9/7/22
To treat moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity
20
Sotyktu
deucravacitinib
9/9/22
To treat moderate-to-severe plaque psoriasis
21
Rolvedon
9/9/22
To decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia
22
Terlivaz
eflapegrastim
9/14/22
To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function
23
Elucirem
gadopiclenol
9/21/22
To detect and visualize lesions, together with MRI, with abnormal vascularity in the central nervous system and the body
24
Omlonti
oomidenepag isopropyl ophthalmic solution
9/22/22
To reduce elevated intraocular pressure in patients with open‑angle glaucoma or ocular hypertension

Core Industry Metrics Updates

Sign up to receive a notification when we update our Core Pharmaceutical Industry Metrics.